Ultragenyx Pharmaceutical, Inc. (RARE)
36.24
+0.04
(+0.11%)
USD |
NASDAQ |
Dec 12, 16:00
36.24
0.00 (0.00%)
After-Hours: 17:26
Ultragenyx Pharmaceutical Research and Development Expense (Quarterly): 207.61M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 1.338B |
| Amicus Therapeutics, Inc. | 23.42M |
| Geron Corp. | 21.07M |
| Ionis Pharmaceuticals, Inc. | 217.13M |
| Vertex Pharmaceuticals, Inc. | 977.70M |